The gut microbiome and melanoma: A review.
gut microbiome
immunotherapy
melanoma
pathogenesis
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
21
06
2022
received:
10
05
2022
accepted:
03
07
2022
pubmed:
7
7
2022
medline:
9
9
2022
entrez:
6
7
2022
Statut:
ppublish
Résumé
Disturbances in the microbial ecosystem have been implemented in chronic inflammation, immune evasion and carcinogenesis, with certain microbes associated with the development of specific cancers. In recent times, the gut microbiome has been recognised as a potential novel player in the pathogenesis and treatment of malignant melanoma. It has been shown that the composition of gut microbiota in early-stage melanoma changes from in situ to invasive and then to metastatic disease. The gut bacterial and fungal profile has also been found to be significantly different in melanoma patients compared to controls. Multiple studies of immune checkpoint inhibitor (ICI) therapies have shown that the commensal microbiota may have an impact on anti-tumor immunity and therefore ICI response in cancer patients. When it comes to chemotherapy and radiotherapy treatments, studies demonstrate that gut microbiota are invaluable in the repair of radiation and chemotherapy-induced damage and therapeutic manipulation of gut microbiota can be an effective strategy to deal with side effects. Studies demonstrate the oncogenic and tumor-suppressive properties of the gut microbiome, which may play a role in the pathogenesis of melanoma. Despite this, investigations into specific interactions are still in its infancy, but starting to gain momentum as more significant and clinically relevant effects are emerging.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1292-1301Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Cancer Research UK. Melanoma skin cancer statistics. [cited 2021 Nov 02]. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer#heading-Zero. 2021.
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005-1011.
Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67(4):326-344.
Selber-Hnativ S, Rukundo B, Ahmadi M, et al. Human gut microbiota: toward an ecology of disease. Front Microbiol. 2017;8:1265.
Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015;31:69-75.
Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-812.
Chen J, Douglass J, Prasath V, et al. The microbiome and breast cancer: a review. Breast Cancer Res Treat. 2019;178:493-496.
Arthur JC, Perez-Chanona E, Mühlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338(6103):120-123.
Buc E, Dubois D, Sauvanet P, et al. High prevalence of mucosa-associated E. coli producing Cyclomodulin and genotoxin in colon cancer. PLoS ONE. 2013;8(2):e56964.
Bultman SJ. Emerging roles of the microbiome in cancer. Carcinogenesis. 2014;35:249-255.
Wen L, Duffy A. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. J Nutr. 2017;147(7):1468S-1475S.
Vitali F, Colucci R, di Paola M, et al. Early melanoma invasivity correlates with gut fungal and bacterial profiles. Br J Dermatol. 2021;186:106-116.
Luo M, Hu MM, Feng X, XiaoLi W, Dong DG, Wang WC. Preventive effect of lactobacillus reuteri on melanoma. Biomed Pharmacother. 2020;126:109929.
Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology. 2018;155(1):33-37.e6.
Chen L, Zhou X, Wang Y, Wang D, Ke Y, Zeng X. Propionate and butyrate produced by gut microbiota after probiotic supplementation attenuate lung metastasis of melanoma cells in mice. Mol Nutr Food Res. 2021;65(15):2100096.
Li Y, Tinoco R, Elmén L, et al. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 −/− mice. Nat Commun. 2019;10(1):1492.
Pereira F v, ACL M, Silva MB, et al. Interleukin-6 and the gut microbiota influence melanoma progression in obese mice. Nutr Cancer. 2021;73(4):642-651.
Yu Y, Champer J, Beynet D, Kim J, Friedman AJ. The role of the cutaneous microbiome in skin cancer: lessons learned from the gut. J Drugs Dermatol. 2015;14:461-465.
Mrázek J, Mekadim C, Kučerová P, et al. Melanoma-related changes in skin microbiome. Folia Microbiol. 2019;64(3):435-442.
Mizuhashi S, Kajihara I, Sawamura S, et al. Skin microbiome in acral melanoma: corynebacterium is associated with advanced melanoma. J Dermatol. 2021;48:e15-e16.
Patra V, Sérézal IG, Wolf P. Potential of skin microbiome, pro-and/or pre-biotics to affect local cutaneous responses to UV exposure. Nutrients. 2020;12(6):1795.
Sherwani MA, Tufail S, Muzaffar AF, Yusuf N. The skin microbiome and immune system: potential target for chemoprevention? Photodermatol Photoimmunol Photomed. 2018;34:25-34.
Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147.
Trivieri N, Pracella R, Cariglia MG, et al. BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies. J Exp Clin Cancer Res. 2020;39(1):285.
Miller JFAP, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell. 2015;27:439-449.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.
Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5(2):187-194.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30:1572-1579.
Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707-723.
Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15:382-396.
Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079-1084.
Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-1089.
Routy B, le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97.
Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104-108.
Gopalakrishnan V, Spencer C, McQuade J, Andrews M, Helmink B, Cogdill A, et al. The gut microbiome of metastatic melanoma patients initiating systemic therapy is influenced by host factors including diet, probiotic and antibiotic use. Society for Immunotherapy of Cancer. Journal for Immunotherapy of Cancer; 2018.
Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368-1379.
Limeta A, Ji B, Levin M, Gatto F, Nielsen J. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight. 2020;5(23):e140940.
Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ (Online). 2018;363:k4226.
Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605-1611.
Sun JY, Yin TL, Zhou J, Xu J, Lu XJ. Gut microbiome and cancer immunotherapy. J Cell Physiol. 2020;235:4082-4088.
Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.
Lee KA, Luong MK, Shaw H, Nathan P, Bataille V, Spector TD. The gut microbiome: what the oncologist ought to know. Br J Cancer. 2021;125:1197-1209.
NICE. Melanoma: Assessment and Management. Assessment and Management; 2015.
Wilson MA, Schuchter LM. Chemotherapy for melanoma. Cancer Treat Res. 2016;167:209-229.
NICE. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. Interventional Procedures Guidance; 2013.
Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14:356-365.
Yang X, Guo Y, Chen C, et al. Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment. Immunology. 2021;164:476-493.
Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971-976.
Blijlevens NMA, Donnelly JP, de Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 2000;25(12):1269-1278.
Sonis ST. Pathobiology of mucositis. Semin Oncol Nurs. 2004;20(1):11-15.
Montassier E, Batard E, Massart S, et al. 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol. 2014;67(3):690-699.
Hong AM. Radiation Therapy in the Management of Melanoma [Internet]. UpToDate. UpToDate Inc.; 2021 [cited 2021 Dec 28]. https://www.uptodate.com/contents/radiation-therapy-in-the-management-of-melanoma
Shi W. Radiation therapy for melanoma. In Ward WH, Farma JM, eds. Cutaneous Melanoma: Etiology and Therapy. Codon Publications; 2017.
Oliver DE, Patel KR, Switchenko J, et al. Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res. 2016;26(1):35-41.
Tonneau M, Elkrief A, Pasquier D, et al. The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: a systematic review. Radiother Oncol. 2021;156:1-9.
Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10:1050.
Ciorba MA, Riehl TE, Rao MS, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012;61(6):829-838.
Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007;13(6):912-915.
Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774-1778.
Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437-1444.
Ng D, Trivedi PM, Sharma AK, Banerjee D. Current use of antibiotic prophylaxis in breast surgery: a nationwide survey. Breast. 2007;16(1):68-72.
Tinsley N, Zhou C, Villa S, et al. Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer. J Clin Oncol. 2018;36(15_suppl):3010.
Huang EY, Inoue T, Leone VA, et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(5):963-972.
Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872-2878.
Jackson MA, Verdi S, Maxan ME, et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun. 2018;9(1):2655.
Rueda-Ruzafa L, Cruz F, Cardona D, et al. Opioid system influences gut-brain axis: dysbiosis and related alterations. Pharmacol Res. 2020;159:104928.
Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69:1510-1519.
clinicaltrials.gov. Identifier NCT03643289, Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics (PRIMM) [Internet]. National Library of Medicine (US); 2018. https://clinicaltrials.gov/ct2/show/NCT03643289?term=gut+microbiome&cond=Melanoma&cntry=GB&draw=2&rank=1
Imhann F, Bonder MJ, Vila AV, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740-748.
Meunier A, Nerich V, Fagnoni-Legat C, et al. Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs. J Antimicrob Chemother. 2019;74(6):1572-1577.
David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-563.
Spencer CN, Gopalakrishnan V, McQuade J, Andrews MC, Helmink B, Khan MAW, et al. Abstract 2838: the gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. In 2019.
Vinson JA, Su X, Zubik L, Bose P. Phenol antioxidant quantity and quality in foods: fruits. J Agric Food Chem. 2001;49(11):5315-5321.
Tzounis X, Rodriguez-Mateos A, Vulevic J, Gibson GR, Kwik-Uribe C, Spencer JPE. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr. 2011;93(1):62-72.
Zhang K, Dai H, Liang W, Zhang L, Deng Z. Fermented dairy foods intake and risk of cancer. Int J Cancer. 2019;144(9):2099-2108.
Nettleton JE, Reimer RA, Shearer J. Reshaping the gut microbiota: impact of low calorie sweeteners and the link to insulin resistance? Physiol Behav. 2016;164:488-493.
Bian X, Chi L, Gao B, Tu P, Ru H, Lu K. Gut microbiome response to sucralose and its potential role in inducing liver inflammation in mice. Front Physiol. 2017;8:487.
Aykan NF. Red meat and colorectal cancer. Oncol Rev. 2015;9:288.
Russell WR, Gratz SW, Duncan SH, et al. High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr. 2011;93(5):1062-1072.
Li Y, Elmén L, Segota I, et al. Prebiotic-induced anti-tumor immunity attenuates tumor growth. Cell Rep. 2020;30(6):1753-1766.e6.
clinicaltrials.gov. Identifier NCT04107168, Microbiome Immunotherapy Toxicity and Response Evaluation [Internet]. National Library of Medicine (US); 2019. https://clinicaltrials.gov/ct2/show/NCT04107168?term=gut+microbiome&cond=Melanoma&cntry=GB&draw=2&rank=2
clinicaltrials.gov. Identifier NCT03341143, Fecal Microbiota Transplant (FMT) in Melanoma Patients [Internet]. National Library of Mecidine (US); 2017. https://clinicaltrials.gov/ct2/show/NCT03341143?term=gut+microbiome&cond=Melanoma&cntry=US&draw=2
clinicaltrials.gov. Identifier NCT04645680, Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study (DIET). National Library of Medicine (US); 2020.
clinicaltrials.gov. Identifier NCT04866810, The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN). National Library of Medicine (US); 2021.
clinicaltrials.gov. Identifier NCT03819296, Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer. National Library of Medicine (US); 2019.
clinicaltrials.gov. Identifier NCT03817125, Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW). National Library of Medicine (US); 2019.
clinicaltrials.gov. Identifier NCT04875728, The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma [Internet]. National Library of Medicine (US); 2016. https://clinicaltrials.gov/ct2/show/NCT04875728?term=gut+microbiome&cond=Melanoma&cntry=US&draw=2
Ogino S, Nowak JA, Hamada T, Milner DA, Nishihara R. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Ann Rev Pathol. 2019;14:83-103.
Mima K, Kosumi K, Baba Y, Hamada T, Baba H, Ogino S. The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. Hum Genet. 2021;140:725-746.
Ogino S, Nishihara R, Vanderweele TJ, et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27:602-611.